Hospital Universitari Germans Trias i Pujol -ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2024

  1. Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table

    Journal of Clinical Lipidology

  2. Atrial secondary tricuspid regurgitation: Pathophysiology, definition, diagnosis, and treatment

    European Heart Journal, Vol. 45, Núm. 11, pp. 895-911

  3. Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation: 1-Year Follow-Up Outcomes

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 1, pp. 60-72

  4. Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

    European Journal of Heart Failure, Vol. 26, Núm. 1, pp. 18-33

  5. Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2

    Journal of the American College of Cardiology

  6. Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials

    European Journal of Heart Failure, Vol. 26, Núm. 7, pp. 1608-1615

  7. Procedural and clinical outcomes of patients undergoing a TAVI in TAVI procedure: Rationale and design of the multicentre, prospective, observational ReTAVI registry

    European Journal of Clinical Investigation, Vol. 54, Núm. 9

2023

  1. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  2. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

    Patient Preference and Adherence, Vol. 17, pp. 839-849

  3. Prevalence and Prognostic Implications of Moderate or Severe Mitral Regurgitation in Patients with Bicuspid Aortic Valve

    Journal of the American Society of Echocardiography, Vol. 36, Núm. 4, pp. 402-410

  4. Use of cardiac imaging in chronic coronary syndromes: the EURECA Imaging registry

    European Heart Journal, Vol. 44, Núm. 2, pp. 142-158

2022

  1. 6-Month Outcomes of the TricValve System in Patients With Tricuspid Regurgitation: The TRICUS EURO Study

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 13, pp. 1366-1377

  2. Vericiguat in heart failure: from scientific evidence to clinical practice

    Revista Clinica Espanola, Vol. 222, Núm. 6, pp. 359-369

  3. Vericiguat in heart failure: from scientific evidence to clinical practice

    Revista Clinica Espanola

2017

  1. Prognostic Significance of Right Heart Thrombi in Patients With Acute Symptomatic Pulmonary Embolism: Systematic Review and Meta-analysis

    Chest, Vol. 151, Núm. 2, pp. 409-416

2014

  1. Historia natural de la enfermedad tromboembólica venosa en el área mediterránea. Una revisión sistemática

    Revista Clinica Espanola, Vol. 214, Núm. 4, pp. 184-191

2013

  1. National consensus on the diagnosis, risk stratification and treatment of patients with pulmonary embolism

    Archivos de Bronconeumologia, Vol. 49, Núm. 12, pp. 534-547

2011

  1. Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de riesgo y ENfermedad arterial (FRENA) registry

    Journal of Cardiovascular Pharmacology, Vol. 57, Núm. 1, pp. 13-19

2009

  1. Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy

    International Journal of Cardiology, Vol. 132, Núm. 1, pp. 38-44